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ABSTRACT The x-ray structure of the Escherichia coli chloride/proton antiporter ClC-ec1 provides a structural paradigm for
the widespread and diverse ClC family of chloride channels and transporters. To maximize the usefulness of this paradigm, it is
important to directly relate structure to function via studies of ClC-ec1 itself; however, few functional studies of this protein have
been performed. In an endeavor to develop new tools for functional analysis of ClC-ec1, we have discovered that this transporter
is inhibited by the stilbenedisulfonate 4,4-diisothiocyanatostilbene-2,29-disulfonic acid (DIDS). In planar lipid bilayers, DIDS
inhibits ClC-ec1 activity reversibly, with an apparent afﬁnity in the micromolar range. Since ClC-ec1 is randomly oriented in the
bilayers, ascertaining whether DIDS inhibits from the intracellular or extracellular side required an indirect approach. Using the
ClC-ec1 structure as a guide, we designed a strategy in which modiﬁcation of Y445C was monitored in conjunction with
inhibition by DIDS. We found that DIDS inhibits transporters speciﬁcally from the intracellular side. Transporters with their
extracellular side exposed to DIDS function normally, maintaining stoichiometric proton/chloride antiport over a wide range of
proton and chloride concentrations. The side-dependent nature of DIDS inhibition will be useful for generating ‘‘functionally
oriented’’ preparations of ClC-ec1, in which DIDS is used to silence transporters in one orientation but not the other.
INTRODUCTION
ClC family members move chloride across membranes in
all cell types, and their physiological roles are diverse (for
reviews, see Pusch and Jentsch (1) and Jentsch et al. (2)).
They are critical for skeletal muscle excitability, neuronal
chloride distribution, endocytosis, epithelial ion transport,
and extreme acid tolerance (3–10). A great advance in the
molecular understanding of the ClC family came with the
crystal structures of two prokaryotic ClC homologs from
Salmonella typhimurium and Escherichia coli (11,12). These
prokaryotic homologs are homodimers, and chloride ions are
seen bound in each subunit. A similar molecular arrangement,
with each subunit forming its own chloride-permeation path-
way, occurs in at least three eukaryotic channels, as indicated
by functional studies on ClC-0, ClC-1, and ClC-2 (13–16).
Although the sequence identity between prokaryotic and
eukaryotic ClC members is only 15–20%, the sequences
surrounding the core of the structure, including the chloride-
binding sites, are highly conserved. In addition, functional
studies of several eukaryotic ClC channels suggest that the
overall fold among ClCs is most likely conserved (12,17–21).
In light of the likely structural similarity between the
prokaryotic and eukaryotic ClC homologs, electrophysio-
logical recordings revealed an unexpected functional dis-
similarity: the E. coli homolog ClC-ec1 is a chloride/proton
antiporter, not a chloride channel (22). Although an antiport
mechanism might seem strikingly different from a channel
mechanism, there are compelling functional similarities
between the ClC-ec1 transporter and the eukaryotic ClC
channels. For example, the eukaryotic ClC channels have
‘‘transporter-like’’ gating properties. Conformational
changes in transporters are typically promoted by increases
in substrate concentrations and are sensitive to transmem-
brane gradients of substrate (23). In the eukaryotic ClC
channels that have been studied, gating is regulated by both
chloride and protons (the ClC antiporter substrates) (24–27)
and also by the transmembrane gradient for chloride (28).
Another similarity between antiporter and channel homologs
is seenwithmutation of a conserved glutamate residue, which
results in loss of proton sensitivity in both ClC-ec1 and ClC-
0 (12,22). In addition, in ClC-ec1, this mutation eliminates
proton transport, thus transforming the chloride-proton
antiporter to a purely chloride-selective uniporter or channel
(22). The similarities between the ClC transporter ClC-ec1
and eukaryotic ClC channels suggest that the structural and
functional boundaries separating ClC channels from trans-
porters may be quite subtle. To understand how subtle
structural differences relate to changes in function, we must
ﬁrst learn more about the mechanism of ClC-ec1, currently
the only ClC member for which both structure and function
can be studied.
Inhibitors are classic experimental tools for studying
mechanism in channels and transporters. However, there is
a dearth of inhibitors for the ClCs in general and, until now,
no known inhibitor of ClC-ec1. The stilbenedisulfonate
DIDS is a widely used anion-transport inhibitor (for reviews,
see Salhany (29), Romero et al. (30), and Jentsch et al. (31)).
Although DIDS inhibits some anion transport proteins
rather nonspeciﬁcally via reaction with lysine residues (32),
we show here that inhibition of ClC-ec1 is reversible and
hence does not rely on covalent modiﬁcation. Identiﬁcation
of the binding site will be useful for probing mechanism
and possibly for designing additional pharmacological
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modulators of ClC family members. As a ﬁrst step toward
identifying the binding site, we sought to determine whether
DIDS inhibits ClC-ec1 from the intracellular side, the extra-
cellular side, or both. One difﬁculty in this endeavor is that
ClC-ec1 is randomly oriented in the reconstituted vesicles
used for functional studies: some of the transporters have
their intracellular side facing inside the vesicles, whereas
others are oriented in the opposite direction, with their extra-
cellular side facing inside the vesicles. Indeed, this situation
is a major obstacle to many studies, as it precludes detailed
determination of chloride, proton, and voltage dependence.
To determine whether DIDS inhibits ClC-ec1 from the
intracellular or extracellular side, we designed a strategy that
uses the known structure of ClC-ec1 combined with cysteine
modiﬁcation. Using this strategy, we show that DIDS inhi-
bits ClC-ec1 from the intracellular side and has no func-
tional effect when applied to the extracellular side. The
side-speciﬁc nature of inhibition by DIDSwill allow for func-
tional orientation of ClC-ec1.
MATERIALS AND METHODS
Protein puriﬁcation
ClC-ec1 containing a C-terminal polyhistidine (His) tagwas overexpressed in
E. coli and puriﬁed essentially as described (33). Brieﬂy, cells were disrupted
using sonication (BransonUltrasonics, Danbury, CT) or a French press (SLM
Instruments, Rochester, NY), and the protein was extracted for 2 h at room
temperature in the presence of 50 mM decylmaltoside (Anatrace, Maumee,
OH). The extract was centrifuged at 20,000 3 g for 45 min, and the protein
was then puriﬁed over a Co21 column (BD Biosciences, San Jose, CA). The
His-tag was cleaved off of the puriﬁed protein with Endoproteinase Lys-C
(Roche, Basel, Switzerland), and the protein was then further puriﬁed over
a Poros HQ anion exchange column (Applied Biosystems, Foster City, CA).
For planar lipid bilayer experiments, only the aliquots corresponding to the
rising phase of the elution peak were used. For experiments involving
cysteine modiﬁcation, dithiothreitol (DTT) (Invitrogen, Carlsbad, CA) was
present throughout all steps of the puriﬁcation to prevent oxidation of the
cysteines. For these preparations, the Co21 beads were replaced by Ni21
beads (Amersham Biosciences, Buckinghamshire, England) that could
tolerate high concentrations of DTT. A total of 5 mM DTT was used for all
steps throughout the Ni21-column puriﬁcation, and 1 mMDTT was used for
the anion exchange column and reconstitution.
Reconstitution
ClC-ec1 reconstitution was similar to that described (33). E. coli polar lipids
(Avanti Polar Lipids, Alabaster, AL) were dried under argon or by rotary
evaporation under vacuum, washed twice with equal volumes of pentane,
and then suspended to a ﬁnal concentration of 20 mg lipid/mL in re-
constitution buffer (for bilayers, either 150 mM KCl, 15 mM citrate, 15 mM
phosphate pH 7.0 with KOH or 450 mM KCl, 25 mM citrate, 25 mM
phosphate pH 7.0 with KOH; for ﬂux assays, as described below).
Octylglucoside (Anatrace) was added (4–5% ﬁnal concentration), and the
suspension was sonicated to clarity using a cylindrical bath sonicator
(Laboratory Supplies, Hicksville, NY). Solubilized ClC-ec1 was added at 50
mg protein per mg lipid for bilayer studies and 10 mg protein per mg lipid for
proton ﬂux assays, and the mixtures were diluted to 10 mg lipid/mL with
reconstitution buffer. Detergent was removed by dialysis over 24 h with
three 1-L buffer changes. The resulting liposomes were freeze-thawed 2–5
times in an acetone/dry ice bath and frozen at 80C until the day of use.
Flux assays
Proton ﬂux assays were performed as described (22) except at symmetric pH
5.7. Brieﬂy, vesicleswere reconstituted in 350mMKCl, 50mMcitrate, 20mM
phosphate pH7.0withKOH.Vesicleswere adjusted to pH5.7with phosphoric
acid, and then intra- and extravesicular solutions were equalized by freezing
and thawing the samples 3–4 times. Either 1% dimethyl sulfoxide (DMSO)
(no-DIDS control) or 2.5 mM DIDS was then added to the vesicles and
equilibrated across the membranes by a series of freeze-thaws. Small
unilamellar vesicles were formed by bath sonication for 5–10 s. Vesicles
(100 mL) were then spun through Sephadex G-50 (Amersham) columns
equilibrated in low-chloride solution (3 mM KCl, 300 mM K2SO4, 2 mM
glutamic acid pH 5.7 with KOH). This decreases the extracellular chloride
concentration, brings the vesicles into a weakly buffered external solution, and
removes unbound DIDS. The efﬂuent from the spin column (;150 mL),
containing the buffer-exchanged vesicles, was immediately added to 1.2mL of
the low-chloride solution. Inward proton movement, driven by outward
chloride ﬂux, was initiated 30–40 s after dilution of the vesicles by the addition
of 1.8 mL valinomycin (Fluka, Buchs, Switzerland, 1.1 mg/mL in ethanol).
After an additional 45–70 s, 1 mL carbonyl cyanide p-(triﬂuoro-methox-
y)phenyl hydrazone (FCCP) (Sigma, St. Louis, MO, 2 mg/mL in ethanol) was
added to collapse the proton gradient. The extravesicular proton concentration
was monitored using a pH electrode (Beckman Coulter, Fullerton, CA)
connected to an Orion 710A pH meter (Thermo Electron, Beverly, MA) and
interfaced with a PC computer running HyperTerminal software (Microsoft,
Redmond,WA). The voltage output from the pHmeter was recorded every 5 s.
The voltage output was converted to external proton concentration using a
standard curve generated on the day of experiments from solutions of known
pH (pH4.0, 7.0, and 10.0). All ﬂux assayswere performed at room temperature
(;22C). The initial rate of change in [H1]ext (Fig. 1 C) was determined over
the 10 s after the addition of valinomycin. The nonspeciﬁc ‘‘leak’’ change in
[H1]ext (Fig. 1C) was determined from the 10–30 s immediately preceding the
addition of valinomycin. Vesicles in which this leak was .8 nM/s were
excluded from analysis.
Bilayer recordings
Bilayer recordings were performed with a horizontal bilayer chamber as
described (34). The trans chamber is grounded and is equivalent to the
‘‘outside’’ by standard electrophysiological convention: negative (inward)
current corresponds to net positive ion ﬂow from the trans to the cis chamber.
Bilayers were formed from 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoetha-
nolamine (POPE) and 1-palmitoyl-2-oleoyl-sn-glycero-3-[phospho-rac-(1-
glycerol)] (POPG) (Avanti Polar Lipids). A 3:1 mixture of POPE/POPG
stored in chloroform was dried, washed 1–2 times with pentane, dried again,
and resuspended in n-decane to 5 or 10mg lipid/mL. Formation of bilayers was
monitored by measuring capacitance using an Axopatch 200B ampliﬁer
interfaced with a Digidata 1322A acquisition board and pClamp software
(Axon Instruments, Union City, CA). Solutions used for each experiment are
described in the ﬁgure legends. No functional differences were observed
between the two types of buffers used (5mMcitrate-5mMphosphate or 5 mM
citrate-40 mMHEPES). Salt bridges containing 300 mMKCl or 300 mMNa-
glutamate (to allow for the use of low-chloride solutions) and 2% agar or
agarose were used in all experiments. A salt gradient (300mMKCl cis, 40mM
KCl trans) was used to promote vesicle fusion. Additionally, 2–4 mL of 3 M
KCl were added immediately above the bilayer to further promote fusion
(increasing theﬁnalKCl concentration in the cis chamber by,6%).Currents in
response to various voltages were recorded after fusions had stopped and the
current at 100 mV was constant over a period of;5 min. Recordings were
made at room temperature (22C).
DIDS
Stock solutions of 250 mM DIDS (Molecular Probes, Eugene, OR) were
made in DMSO. They were kept dark and frozen at 20C or 80C until
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immediately before use, when they were diluted to a ﬁnal concentration of
6.25 mM  2.5 mM.
Cysteine modiﬁcation
[2-(trimethylammonium)ethyl] methanethiosulfonate bromide (MTSET)
was obtained from Toronto Research Chemicals (Toronto, Ontario, Canada).
Stock solutions (0.1–1.0 M) were made in distilled water, aliquoted, and
stored at 80C until immediately before use. A total of 1–4 mM MTSET
was added to bilayers in which both the cis and the trans chambers contained
300 mM KCl, 5 mM citrate, 40 mM HEPES pH 6.0. For this experiment,
a pH of 6.0 was used as a happy medium for obtaining both a sufﬁcient
amount of current (the activity of ClC-ec1 increases as the pH is lowered)
and a sufﬁciently fast rate of reactivity of MTSET (which generally
decreases as the pH is lowered). Recordings were made at least 5 min after
addition of the MTSET, when the effect of MTSET had reached steady state.
Determining reversibility and apparent afﬁnity
of DIDS in ClC-ec1
To determine the reversibility of inhibition by DIDS, 250 mM DIDS was
applied to the trans chamber for ;5 min before washing away the unbound
DIDS. After washout, currents were measured only every 2–5 min to mini-
mize the probability of the bilayer breaking. Approximate rates of rever-
sibility were determined by ﬁtting the current decay to a single exponential.
Since only a few time points were used, and since perfusion took ;2 min,
these rates are estimates.
To determine the apparent afﬁnity of DIDS in ClC-ec1, currents were
measured before and after addition of DIDS to the trans chamber. Each
bilayer received 1–3 consecutive additions of DIDS. The data for inhibition
by 6–250 mM DIDS (Fig. 3 C) were obtained from eight separate bilayers,
and the data for inhibition by 2.5 mM DIDS (Fig. 3 C) were obtained from
20 separate bilayers. The concentrated stock of DIDS used in these experi-
ments was made fresh or stored at 20C or 80C for ,1 day before use.
Determination of reversal potentials in
‘‘oriented samples’’
DIDS was added to either the cis or the trans chamber in 2–5 bilayers under
each condition listed in Table 3. Additional perfusions were then made to
alter the chloride and/or proton conditions on the opposite side of the bilayer:
for example, if DIDS was added to the cis chamber, the chloride or proton
concentration of the trans solution was changed by perfusion. Reversal
potentials were determined from current-voltage curves.
RESULTS
DIDS inhibits ClC-ec1
To test whether DIDS inhibits ClC-ec1, we expressed and
puriﬁed ClC-ec1 and reconstituted the protein into lipid
vesicles. Chloride-driven proton ﬂux through ClC-ec1 was
measured using a pH electrode in a weakly buffered ex-
travesicular solution (22). At symmetric pH, an outwardly
directed chloride gradient favors movement of chloride out
of the vesicles and concomitant movement of protons into
the vesicles through ClC-ec1 (Fig. 1 A). Bulk chloride efﬂux
and proton inﬂux through ClC-ec1 do not occur until the
potassium ionophore valinomycin is added to dissipate the
transmembrane electrical potential. With ClC-ec1-contain-
ing vesicles, the external proton concentration ([H1]ext) de-
creased after valinomycin was added (Fig. 1 B, circles). The
proton ionophore FCCP was added at the end of the
experiment to release intravesicular protons and conﬁrm that
the change in [H1]ext was in fact due to proton accumulation.
Addition of 2.5 mM DIDS to both sides of the ClC-ec1
vesicles (see Materials and Methods) inhibited this chloride-
FIGURE 1 DIDS inhibition of ClC-ec1. (A) Cartoon illustrating ion
movement in the proton ﬂux assays. An outwardly directed Cl gradient
drives H1 uptake through ClC-ec1. The chloride and proton conditions listed
are initial conditions before the potassium-selective ionophore valinomycin
was added to allow bulkmovement of Cl andH1 throughClC-ec1. FCCP is
added at the end of each experiment to collapse the proton gradient and
release accumulated protons. (B) Inhibition of chloride-driven proton ﬂux.
Vesicles reconstituted with ClC-ec1 were treated with 1% DMSO (no-DIDS
control, d) or 2.5 mM DIDS ()). Control vesicles lacking ClC-ec1 were
treated with 1% DMSO (n). To align the traces for visual comparison, the
change in proton concentration (D[H1]ext), rather than the absolute proton
concentration is plotted. The change is in reference to the time point
immediately before addition of valinomycin. Traces were aligned along the x
axis such that valinomycin was added at the same time point. Straight lines
connect the data points in all ﬁgures unless otherwise stated. (C) The rate of
D[H1]ext is summarized for several ﬂux assays under each condition (mean6
SE, or6 range for n¼ 2). Negative values on the y axis represent a decrease in
[H1]ext over time, and positive values represent an increase in [H
1]ext. The
rates measured before (open bars) and after (solid bars) the application of
valinomycin differ signiﬁcantly only in the case of ClC-ec1-containing
vesicles in the absence of DIDS. The numbers in parentheses represent the
number of ﬂux assays performed under each condition.
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driven proton inﬂux (diamonds). With control vesicles
lacking ClC-ec1, no valinomycin-induced proton inﬂux
was observed (triangles). In each experiment, the slight
change in [H1]ext that occurred before the addition of
valinomycin likely resulted from a combination of drift in the
electrode and proton leak (via permeation of HCl or CO2)
across the vesicle membrane (35). This background D[H1]ext
varied in magnitude and direction from experiment to ex-
periment and is summarized for each condition in Fig. 1 C.
D[H1]ext is signiﬁcantly different before and after addition of
valinomycin only in the case of ClC-ec1-containing vesicles
in the absence of DIDS.
DIDS inhibits ClC-ec1 in a side-dependent manner
To examine inhibition byDIDSmore closely, we used bilayer
recordings, which allow direct control of the solutions on both
sides of the membrane and the voltage across the membrane.
ClC-ec1 currents in response to various test voltages are
shown in Fig. 2A (left), and the current-voltage relationship is
plotted in Fig. 2 B (circles). In these recordings, some of the
transporters have their intracellular side facing the trans
chamber, whereas the remaining transporters have their
intracellular side facing the cis chamber (Fig. 2 D, left).
This random orientation occurs because dispersion in de-
tergent renders the proteins free to insert in either direction.
Such dispersion is necessary for puriﬁcation of ClC-ec1
away from ion channels that overwhelm and mask the ClC-
ec1 currents (33). Although it is theoretically possible that the
proteins reconstitute in a preferred orientation, this is not
likely given that both orientations are observedwhen ClC-ec1
is reconstituted to form two-dimensional crystals (36), and
our results in Figs. 4 and 5 additionally refute this possibility.
Addition of saturating concentrations of DIDS (2.5 mM)
to the cis side inhibited ;40% of the current (Fig. 2 A,
center, and Fig. 2 B, diamonds). Subsequent addition of 2.5
mM DIDS to the trans chamber inhibited an additional
;50% of the current (88% total block, Fig. 2 A, right, and
Fig. 2 B, crosses). DMSO alone had no signiﬁcant effect on
ClC-ec1 currents (Fig. 2 C). Table 1 summarizes results from
several experiments. These data are consistent with a model
in which DIDS inhibits the ClC-ec1 activity in a side-
dependent manner (Fig. 2 D).
We expect that some variability in the percentage in-
hibition might occur because of variation in the fraction of
transporters in each orientation. Although on average the
bilayers will contain 50% of the transporters in each ori-
entation, some bilayers will have more transporters oriented
in one direction than in the other. Indeed, we saw anywhere
from 27–55% inhibition from DIDS added only to the cis
chamber and 42–75% inhibition fromDIDS added only to the
trans chamber. If all of this variation was due to random
variability in the orientation of transporters, then we should
have observed signiﬁcantly less variation when DIDS was
added to both sides of the membrane. However, we observed
a large variation in inhibition (60–88%) even whenDIDSwas
added to both sides of the membrane. Potential sources of
variability include leak in the bilayers and instability of DIDS
solutions (see Discussion). Although we are not yet certain of
the reason for this variability, DIDS consistently inhibits the
FIGURE 2 Side-dependent inhibition of ClC-ec1 by
DIDS. (A) ClC-ec1 currents in response to the voltage
protocol shown below the center current trace. This
voltage protocol was used for all experiments unless
otherwise stated. (Left) Initial current family. (Center)
After addition of 2.5 mM DIDS to the cis chamber.
(Right) After subsequent addition of 2.5mMDIDS to the
trans chamber. The cis chamber contained 300mMKCl,
5 mM citrate, and 40 mM HEPES pH 5.0, and the trans
chamber contained 40 mM KCl, 5 mM citrate, and 40
mM HEPES pH 5.7. (B) Current-voltage plots, where
currents were measured at the end of the 1.5-s voltage
pulses shown in A. (C) Current-voltage plots from a
separate bilayer before and after addition of 1%DMSO to
the cis chamber and subsequently to the trans chamber.
Solutions were identical to those used in A and B. (D)
Cartoon depicting a model in which DIDS inhibits ClC-
ec1 speciﬁcally from one side. Transporters insert into the
bilayers with random orientation; some have their
intracellular side facing the trans chamber, whereas
others have their intracellular side facing the cis chamber.
In this model, DIDS binds to one face of ClC-ec1,
inhibiting all of the transporters in one orientation when
added to the cis chamber and all of the transporters in the
opposite orientation when added to the trans chamber.
For simplicity, one DIDS molecule is shown binding to
each ClC-ec1 molecule.
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majority of ClC-ec1 activity both in ﬂux assays and lipid
bilayer recordings.
DIDS inhibits ClC-ec1 reversibly
DIDS is known to modulate anion channel and transporter
activity by both irreversible and reversible mechanisms (32).
We found that ClC-ec1 inhibition by DIDS reverses com-
pletely (Fig. 3, A and B), with a time constant of 9 6 3 min
at pH 5.0 and of 2 6 1 min at pH 7.0 (mean 6 SD, n ¼ 3
bilayers for each condition). The apparent afﬁnity of DIDS
for ClC-ec1 is ;30 mM under the conditions described in
Fig. 3 C. Although changes in chloride or proton concen-
trations could alter this value (by affecting the distribution of
transporter conformations or the occupancy of ions in the
permeation pathway), 30 mM is of the same magnitude
observed for reversible inhibition of other chloride transport
proteins, including ClC-Ka (;100 mM) (37) and the
endogenous volume regulated anion channels in T-lympho-
cytes and HEK293 cells (;25 mM) (38,39).
DIDS acts from the intracellular side
To determine whether DIDS inhibits ClC-ec1 speciﬁcally
from the intracellular face or the extracellular face, we used
the known structure of ClC-ec1 together with a cysteine-
modiﬁcation approach. In the ClC-ec1 structure, Y445 co-
ordinates one of the bound chloride ions near the intracellular
side (Fig. 4 A). In ClC-0, a cysteine at the homologous
position (Y512) can be modiﬁed by the membrane-
impermeant reagent MTSET applied to the intracellular
side (18). In wild-type (WT) ClC-ec1, addition of MTSET
had no functional effect (Fig. 4 B). In contrast, in transporters
containing the Y445C mutation (Y445C-ClC-ec1), addition
of MTSET to the trans chamber increased the current at
positive voltages (Fig. 4 C, blue squares), and subsequent
addition of MTSET to the cis chamber increased the current
at negative voltages (red triangles). Similar results were
observed in several bilayers (Table 2), and this voltage-
dependent potentiation did not depend on whether MTSET
was added to the cis chamber or trans chamber ﬁrst.
Potentiation by MTSET was completely reversible by DTT.
These results are consistent with a model in which MTSET
modiﬁcation of Y445C occurs speciﬁcally from one side of
ClC-ec1 (Fig. 4 D). In contrast, our data are not consistent
with a model in which MTSET is able to modify Y445C
from either the intracellular or extracellular side of ClC-ec1;
this model would predict that addition of MTSET to either
the cis or the trans chamber would be sufﬁcient for complete
modiﬁcation of Y445C, and subsequent addition to the
opposite side of the bilayer should have no further functional
TABLE 1 Inhibition of wild-type ClC-ec1 by DIDS
% Inhibition at
100 mV
% Inhibition at
1100 mV Vrev (mV)
No DIDS 17.5 6 3.4 (23)
DIDS cis only 38 6 7 (11) 40 6 10 (10) 16.7 6 4.4 (9)
DIDS trans only 50 6 8 (12) 50 6 10 (12) 17.9 6 3.0 (12)
DIDS both sides 74 6 10 (13) 73 6 10 (12) 13.5 6 5.6 (13)
DIDS inhibits ClC-ec1 in a side-dependent manner. Values represent mean
6 SD. Numbers in parentheses represent the number of bilayers tested.
Conditions were as in Fig. 2, except in some experiments solutions were
buffered with 5 mM phosphate in place of 40 mM HEPES. In each case, 2.5
mM DIDS was added to the cis chamber (300 mM KCl pH 5.0), the trans
chamber (40 mM KCl pH 5.7), or both. The order of addition did not affect
the amount of inhibition. The fact that the reversal potential (Vrev) does not
change signiﬁcantly upon addition of DIDS suggests that much of the resi-
dual current after DIDS inhibition is due to currents through ClC-ec1.
FIGURE 3 Reversibility of DIDS inhibition of ClC-ec1. (A) Initial
currents through wild-type ClC-ec1 (s) were blocked;40% by addition of
250 mM DIDS added to the trans chamber (h). Complete reversal of
inhibition was observed ;40 min after washing out the DIDS ()). The cis
chamber contained 300 mM KCl, 5 mM citrate, and 40 mM HEPES pH 5.0,
and the trans chamber contained 40 mM KCl, 5 mM citrate, and 40 mM
HEPES pH 5.0. (B) Identical to A, except that the trans chamber contained
solution at pH 7.0. Initial currents (s) were blocked ;35% by addition of
250 mM DIDS to the trans chamber (h). Complete reversal was observed
;15 min after washing out the DIDS ()). (C) Concentration dependence of
inhibition by DIDS. In these experiments, the cis chamber contained 300
mM KCl, 5 mM citrate, and 40 mM HEPES pH 5.0; the trans chamber
contained 40 mM KCl, 5 mM citrate, and 40 mM HEPES pH 5.7. Data are
from several bilayers (see Materials andMethods) in which DIDS was added
to the trans chamber only, such that maximal inhibition is ;50%. The
inhibition was measured at 1100 mV ()) or 100 mV (s). The solid line
is a ﬁt of the data to a rectangular hyperbola: F ¼ Fmax/(1 1 (KM/[DIDS])),
where F is the percentage current inhibition, Fmax is the maximal inhibition
(48%), and KM is the apparent afﬁnity for DIDS (26 mM).
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effect. Hence, potentiation of the Y445C mutant is due to
MTSET reacting speciﬁcally with Y445C from one side of
the protein. Based on the structure of ClC-ec1 and the
experimental observation that the homologous position in
ClC-0 (Y512C) is modiﬁed from the intracellular side
(18,21), we conclude that in ClC-ec1, MTSET modiﬁes
Y445C speciﬁcally from the intracellular side.
We reasoned that we could use the sidedness of this
MTSET effect on Y445C transporters to determine whether
DIDS inhibits from the intracellular or extracellular side.
Although the shape of the current-voltage relationship for
Y445C transporters differs somewhat from that observed
with WT transporters (Fig. 4 C versus B), the Y445C
currents are inhibited by DIDS in a side-speciﬁc manner as
observed with WT, so it is unlikely that the structure of the
DIDS-binding site is altered signiﬁcantly by this point
mutation. To determine whether DIDS acts from the in-
tracellular side (like MTSET) or the extracellular side, we
performed an experiment consisting of four consecutive
solution changes (Fig. 5 A). In this experiment, addition of a
saturating concentration of DIDS to the cis chamber blocked
;35% of the current (black circles without DIDS, green
diamonds with DIDS, states 1 and 2 in the cartoon). If DIDS
inhibits ClC-ec1 from the intracellular side, subsequent
application of MTSET to the same (cis) chamber should have
no effect, since DIDS has already inhibited the transporters
with their intracellular side facing the cis chamber (and since
DIDS may additionally prevent MTSET from reacting). If,
however, DIDS inhibits from the extracellular side, the
MTSET-sensitive transporters should still be available and
normal potentiation should occur when MTSET is added to
the same chamber as DIDS. We observed that subsequent
addition of MTSET to the cis chamber had no effect on
current (Fig. 5 A, red triangles, state 3 in the cartoon). Thus,
DIDS either inhibited all the MTSET-reacted transporters or
prevented MTSET from reacting. Either way, these results
suggest that DIDS and MTSET act on the same (intracellular)
side. If this interpretation is correct, then transporters oriented
in the opposite direction (with their intracellular side facing
the trans chamber) should be potentiated when MTSET is
subsequently added to the trans chamber. Indeed, subsequent
addition of MTSET to the trans chamber potentiated the
current at positive voltages (Fig. 5 A, blue squares, state 4 in
the cartoon), exactly as seen in the absence of any cis
additions (Fig. 4 C, blue squares). Thus, DIDS has no
signiﬁcant effect from the extracellular side of ClC-ec1. A
ﬁnal addition of DIDS to the trans chamber inhibited nearly
all of the remaining current (Fig. 5 A, purple crosses, state 5 in
cartoon). This demonstrates that DIDS can still bind and
inhibit from the intracellular side of ClC-ec1 after MTSET has
reacted.
To determine whether the order of DIDS and MTSET
additions would affect our conclusion, we varied the order of
the perfusions. In the example shown in Fig. 5 B, MTSET
was ﬁrst added to the cis chamber, which potentiates the
current at negative voltages with little effect at positive
voltages (black circles, before MTSET; red triangles, after
addition of MTSET to the cis chamber, states 1 and 2 in
cartoon). Subsequent addition of DIDS to the cis chamber
TABLE 2 Potentiation of Y445C-ClC-ec1 by MTSET
Potentiation at
120 mV
Potentiation at
1120 mV
MTSET cis 2.60 6 0.39 (9) 1.18 6 0.11 (8)
MTSET trans 1.15 6 0.10 (4) 1.72 6 0.32 (3)
MTSET cis if DIDS
previously added cis
0.77 6 0.13 (4) 0.89 6 0.09 (4)
MTSET trans if DIDS
previously added cis
0.95 6 0.14 (4) 1.99 6 0.34 (4)
Potentiation is deﬁned as the current after addition of MTSET divided
by the current before addition of MTSET (mean 6 SD). Numbers in paren-
theses represent the number of bilayers tested. Conditions were as in Fig. 4.
FIGURE 4 Side-speciﬁc potentiation of Y445C by MTSET. (A) Structure
of ClC-ec1 (Protein Data Bank 1OTS) (12). Y445 is shown spaceﬁlled in
red. The chloride ions (two per subunit) are spaceﬁlled in green. (B) Wild-
type ClC-ec1 currents were recorded in response to 3-s voltage pulses
from120mV to1150 mV in 30mV steps, with a holding voltage of 0 mV.
Currents plotted were from the end of the 3-s pulse: initial current (black
circles); after addition of 2 mM MTSET to the cis chamber (red triangles);
after subsequent addition of 2 mM MTSET to the trans chamber (blue
squares). The cis and trans chambers both contained 300 mM KCl, 5 mM
citrate, and 40 mM HEPES pH 6.0. (C) Addition of 2 mM MTSET causes
side-speciﬁc potentiation of Y445C-ClC-ec1. Currents were recorded in
response to 3-s voltage pulses from 150 mV to1150 mV in 30 mV steps,
with a holding voltage of 0 mV. Initial current (black circles); after addition
of 2 mM MTSET to the trans chamber (blue squares); after subsequent
addition of 2 mMMTSET to the cis chamber (red triangles). Solutions were
as described in B. (D) Cartoon depicting a model in which MTSET modiﬁes
Y445C speciﬁcally from the intracellular side. For simplicity, one MTSET
molecule is shown binding to each ClC-ec1 molecule.
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inhibited the MTSET-potentiated current (green diamonds,
state 3 in cartoon), as expected if DIDS and MTSET are
acting on the same transporters. Further conﬁrmation comes
from our observation that the usual potentiation occurs when
MTSET is next added to the trans chamber (blue squares,
state 4 in cartoon). Similar results were observed in several
bilayers (Table 2). These data together with the structure of
ClC-ec1 strongly support the conclusion that DIDS inhibits
ClC-ec1 speciﬁcally from the intracellular side.
The side speciﬁcity of DIDS inhibition suggests that it will
be useful for ‘‘functional orientation’’ of ClC-ec1 prepara-
tions. To functionally orient ClC-ec1, DIDS can be added to
one side of the bilayer, silencing transporters with their in-
tracellular side exposed to DIDS and allowing transporters
with their extracellular side exposed to DIDS to be studied in
isolation. For DIDS to be useful for this purpose, it is critical
that transporters with their extracellular side exposed to
DIDS function normally. For example, one could imagine
a scenario in which DIDS inhibits transporters only when
exposed to the intracellular side but also binds somewhere on
the extracellular side and modulates chloride-proton cou-
pling. To verify that extracellular exposure of DIDS does not
alter the chloride-proton coupling of ClC-ec1, we measured
the reversal potential before and after addition of DIDS
to one side of the bilayer (‘‘unoriented’’ and ‘‘oriented’’
conditions, respectively) under several chloride and proton
conditions (Fig. 6, Table 3). In all cases, reversal-potential
data were well described by the thermodynamic relationship
for 2:1 stoichiometric antiport, in which two chloride ions
are transported in one direction for every proton transported
in the opposite direction (22):
3Vrev ¼ 2ECl 1EH1 ; (1)
where Vrev is the experimentally measured reversal potential
and ECl and EH1 are the calculated reversal potentials for
chloride and protons, respectively, as explained in Table 3.
Hence, even when the extracellular side of ClC-ec1 is
exposed to millimolar concentrations of DIDS, ClC-ec1 still
acts to transport two chloride ions across the membrane for
every proton countertransported.
FIGURE 5 DIDS and MTSET act from the same
side. Each panel shows Y445C-ClC-ecl currents before
and after indicated solution changes. Conditions were
as described in Fig. 4 B. In each cartoon, the transporter
depicted on the left has its intracellular side facing the
trans chamber, and the transporter on the right has its
intracellular side facing the cis chamber. For simplic-
ity, only one DIDS and one MTSET are shown bound
to each ClC-ec1 transporter. (A) Initial current (black
circles); after addition of 2.5 mM DIDS to the cis
chamber (green diamonds); after subsequent addition
of 4 mM MTSET to the cis chamber (red triangles);
after subsequent addition of 2 mMMTSET to the trans
chamber (blue squares); and after subsequent addition
of 2.5 mMDIDS to the trans chamber (purple crosses).
(B) Initial current (black circles); after addition of 1
mM MTSET to the cis chamber (red triangles); after
subsequent addition of 1 mM DIDS to the cis chamber
(green diamonds); and after subsequent addition of 2
mM MTSET to the trans chamber (blue squares).
FIGURE 6 Normal proton-chloride coupling is observed in ‘‘oriented’’
transporters. Reversal potential data (Table 3) are plotted according to Eq. 1.
The dashed line represents the expected curve for a transporter that stoi-
chiometrically couples the movement of two chloride ions in one direction to
one proton in the opposite direction. Vrev is the experimentally measured
reversal potential; ECl and EH1 are the calculated reversal potentials for
chloride and protons, respectively, as explained in Table 3. ‘‘Unoriented’’
refers to measurements made in the absence of DIDS; ‘‘oriented’’ refers to
measurements made in the presence of 2.5 mM DIDS in either the cis or the
trans chamber. In all cases, DIDS inhibited approximately half (35–67%) of
the current, consistent with the idea that DIDS inhibits speciﬁcally from one
side under all of these conditions.
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DISCUSSION
Inhibition of ClC-ec1 by DIDS
ClC-ec1 is inhibited by DIDS in ﬂux assays and bilayer
recordings. We used the mutant Y445C, which is potentiated
in a side-speciﬁc manner by MTSET (Fig. 4), to identify the
side-speciﬁcity of inhibition by DIDS. Since DIDS and
MTSET act from the same side of Y445C-ClC-ec1 (Fig. 5),
we conclude that DIDS acts from the intracellular side. Thus,
addition of DIDS to the cis chamber of the bilayer results in
a ‘‘functionally oriented’’ preparation in which most of the
active transporters are oriented with their extracellular face
toward the cis chamber.
One complication of using DIDS for functional orientation
is the variability in the magnitude of inhibition (60–88%
when added to both sides of the bilayer). We do not have
a satisfactory explanation for all of this variability, but it likely
results at least in part from variability in bilayer leak and in
efﬁcacy of the DIDS solution. Variability in the efﬁcacy of
DIDS inhibition in ClC-ec1 could arise from a combination of
several known properties of DIDS: 1), DIDS will react with
accessible deprotonated primary amines. The lipids used for
vesicles and bilayers contain substantial amounts of phospha-
tidylethanolamine, which could serve as a DIDS sink. 2),
Exposure to light varies the ratio of the trans and cis forms of
DIDS, and these isomers could have different efﬁcacies for
ClC-ec1. The trans isomer is known to inhibit other chloride
transport proteins by several orders of magnitude more efﬁ-
ciently than the cis isomer (32). 3), DIDS is not stable in
aqueous solution. We stored the DIDS solutions frozen in
DMSO, and it is possible that small amounts of water in these
stock solutions caused variability in the purity of the DIDS.
Despite these sources of variability, we found that DIDS
consistently inhibited the majority of the ClC-ec1 activity in
a side-dependent manner.
A second complication in using DIDS for functional
orientation is that maximal inhibition is not 100%. The fact
that the reversal potential was not signiﬁcantly altered after
saturating concentrations of DIDS were added to both sides
(Table 1) suggests that much of the residual current was due
to activity through ClC-ec1 rather than leak in the bilayers.
To use DIDS for functional orientation, it will be best to use
a subtraction protocol, which would overcome complica-
tions from the fact that maximal inhibition by DIDS is
,100% and from the aforementioned variability in maximal
inhibition by DIDS. For example, in bilayers oriented with
DIDS in the cis chamber, the ‘‘DIDS-sensitive current’’
would be obtained by subtracting current observed after
addition of DIDS to the trans chamber. An important point is
that we have not yet demonstrated that inhibition by DIDS is
side speciﬁc under all possible combinations of chloride and
proton concentrations and that this would need to be veriﬁed
for each condition. Nevertheless, under all conditions tested
in Table 3 (ranging 3–300 mM Cl and pH 4–pH 7), appli-
cation of DIDS to one side of the bilayer inhibited 35–67%
of the current, consistent with the idea that DIDS inhibits
transporters speciﬁcally from the intracellular side under a
variety of conditions.
MTSET modiﬁcation of Y445C-ClC-ec1
Modiﬁcation of Y445C by the positively charged reagent
MTSET causes voltage-dependent potentiation of Y445C-
ClC-ec1. In ClC-0, the homologous mutation, Y512C, is
inhibited nearly completely by MTSET (18) and also by
the negatively charged reagent sodium (2-sulfonatoethyl)
methanethiosulfonate (MTSES) (18,21). Surprisingly, in
Y445C-ClC-ec1, addition of MTSES had little functional
effect, inhibiting the currents by,20% when applied to both
sides of the membrane. MTSES was able to react with all of
the Y445C sites, as demonstrated by the fact that application
of MTSES prevented MTSET from potentiating Y445C-
ClC-ec1 current (K. Matulef and M. Maduke, unpublished
data). Thus, these different effects of MTSET and MTSES
likely arise from the difference in charge on these reagents.
The charge at residue 445 could affect currents by altering
the intrinsic voltage dependence of ClC-ec1 or by altering
the local concentrations of chloride and protons. Further
work is necessary to elucidate the mechanism of potentiation
by MTSET.
Comparison to inhibition of other ClCs by DIDS
ClC-Ka and ClC-K1 are inhibited by DIDS from the extra-
cellular side (37). Two residues near the outer mouth of the
pore are necessary for potent inhibition of these channels by
DIDS (37), and these residues are not conserved in ClC-ec1,
TABLE 3 Application of DIDS to the extracellular side of
ClC-ec1 does not affect proton-chloride coupling
[Cl]
(mM)
(cis/trans)
pH
(cis/trans)
Vrev (mV)
‘‘unoriented’’
Vrev (mV)
‘‘oriented’’
ECl
(mV)
EH1
(mV)
300/40 5/5 28.1 6 2.1 (15) 28.9 6 5.3 (7) 46.8 0
300/40 5/7 8.8 6 2.6 (3) 9.1 6 1.4 (4) 46.8 117.1
300/40 5/5.7 19.6 6 4.3 (6) 17.7 6 5.5 (6) 46.8 41.0
300/40 5.7/5 46.7 6 2.3 (3) 47.0 6 3.6 (3) 46.8 41.0
300/40 5/4 47.7 6 2.6 (3) 48.1 6 2.4 (4) 46.8 58.6
300/40 4/5 11.2 6 1.4 (3) 9.2 6 4.1 (3) 46.8 58.6
300/40 4/7 25.2 6 0.8 (3) 24.1 6 0.9 (4) 46.8 175.7
300/3 5/5 66 6 4.4 (8) 59.2 6 11.0 (7) 109.2 0
300/300 4/4 2.3 6 0.96 (4) 1.5 6 1.5 (4) 0 0
Reversal potentials under a wide range of chloride and proton concen-
trations and gradients. Solutions were buffered with 5 mM citrate-5 mM
phosphate. Vrev ‘‘unoriented’’ represents the mean reversal potential 6 SD
(No. of bilayers) in the absence of DIDS. Vrev ‘‘oriented’’ represents the
mean reversal potential 6 SD (No. of bilayers) when 2.5 mM DIDS was
added to either the cis or the trans chamber. ECl and EH1 represent the
calculated reversal potentials for Cl and H1, respectively. Activity
coefﬁcients of 0.688, 0.818, and 0.940 were used for 300 mM, 40 mM, and
3 mM Cl, respectively (45).
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ClC-0, or other homologs that are insensitive to extracellular
DIDS: ClC-2, ClC-3, and ClC-5 (40–42). Thus, it is not
surprising that DIDS does not inhibit ClC-ec1 or ClC-0 from
the extracellular side.
Although DIDS is a widely used chloride-transport
inhibitor, the only other ClC homolog for which intracellular
sensitivity to DIDS has been reported is ClC-0 (43,44). Like
ClC-ec1, DIDS inhibits ClC-0 speciﬁcally from the in-
tracellular side, but unlike ClC-ec1, inhibition of ClC-0 is
irreversible (43). Irreversible inhibition usually occurs as
a result of reaction of one or both of the isothiocyanate
groups with susceptible unprotonated lysines. The reversible
inhibition of ClC-ec1 by DIDS suggests that either the
DIDS-binding site in ClC-ec1 is not close to an unprotonated
lysine residue or that DIDS is rigidly bound, such that its
isothiocyanate groups cannot become suitably oriented for
reaction with a nearby lysine. We cannot rule out the
possibility that DIDS can slowly inhibit ClC-ec1 irrevers-
ibly, but if so, it must do so on a timescale much slower than
is observed with ClC-0. In ClC-0, 12 mM DIDS inhibits
irreversibly within 40 s (43); in these experiments with ClC-
ec1 (Fig. 3, A and B), 250 mMDIDS applied for;5 min was
completely reversible.
It remains to be seen whether DIDS inhibits other ClC
homologs from the intracellular side and whether DIDS
binds at homologous sites in ClC-0 and ClC-ec1. Since good
pharmacological tools are lacking for ClC members,
identifying the binding site for DIDS in ClC-ec1, which is
amenable to crystallization, may aid in designing better inhi-
bitors for these critical proteins.
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